| Literature DB >> 29743986 |
Salvatore Giovanni Vitale1, Stella Capriglione2, Isabel Peterlunger3, Valentina Lucia La Rosa4, Amerigo Vitagliano5, Marco Noventa5, Gaetano Valenti6, Fabrizio Sapia6, Roberto Angioli2, Salvatore Lopez2, Giuseppe Sarpietro6, Diego Rossetti7, Gabriella Zito8.
Abstract
Endometriosis is a condition characterized by the presence of endometrial tissue outside the uterine cavity, leading to a chronic inflammatory reaction. It is one of the most widespread gynecological diseases with a 10-15% prevalence in the general female population, rising up to 30-45% in patients with infertility. Although it was first described in 1860, its etiology and pathogenesis are still unclear. It is now accepted that inflammation plays a central role in the development and progression of endometriosis. In particular, it is marked by an inflammatory process associated with the overproduction of an array of inflammatory mediators such as prostaglandins, metalloproteinases, cytokines, and chemokines. In addition, the growth and adhesion of endometrial cells in the peritoneal cavity due to reactive oxygen species (ROS) and free radicals lead to disease onset, its ensuing symptoms-among which pain and infertility. The aim of our review is to evaluate the role of oxidative stress and ROS in the pathogenesis of endometriosis and the efficacy of antioxidant therapy in the treatment and mitigation of its symptoms.Entities:
Mesh:
Year: 2018 PMID: 29743986 PMCID: PMC5883985 DOI: 10.1155/2018/7924021
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Markers of OS in endometriosis patients.
| Reference | Type of biospecimen | OS marker |
|---|---|---|
| Rong et al. 2002 [ | Peritoneal Fluid | ↑ lipoproteins, particularly low-density lipoprotein (LDL) |
| Polak et al. 2013 [ | Peritoneal fluid | ↑ 8-iso-PGF2 |
| Santulli et al. 2015 [ | Peritoneal fluid | ↑ thiols, advanced oxidation protein products, protein carbonyl, and nitrates/nitrites in deep endometriosis |
| Jackson et al. 2005 [ | Peritoneal fluid | ↓ antioxidants |
| ↑ lipid peroxides |
Major genetic alterations/mutations in different stages of endometriosis associated ovarian cancer (EAOC).
| Factor | Genetic alteration | Current data |
|---|---|---|
| Tumor suppressor genes | PTEN | Phosphatase and tensin homolog is mutated in many cancers, particularly in endometrial and endometrioid ovarian cancer; its inactivation occurs early during tumorigenesis [ |
| ARID1A | ARID1A mutations are significantly more common in two ovarian cancer subtypes associated with endometriosis (clear cell and endometrioid). Endometriosis synchronous with ovarian cancer presented more frequent mutations in clones derived from endometriosis samples directly adjacent of the tumor than in those from distant endometriotic lesions [ | |
|
| ||
| DNA repair | hMLH1 | hMLH1 corrects errors in DNA replication; hypermethylation of its promoter occurs early in endometriosis malignant transformation [ |
|
| ||
| Loss of heterozygosity (LOH) | A trend to increased LOH frequencies has been reported in solitary endometriosis lesions, endometriosis-associated carcinoma, and endometrioid ovarian cancer. Common LOH events can be identified in endometriosis synchronous with ovarian cancer [ | |
| ARID1A and PIK3CA | ARID1A and PIK3CA mutations were found in ovarian clear cell carcinoma and in tumor-adjacent and distant endometriotic lesions, regardless of cytological atypia [ | |
| ARID1A and p53 | Both ARID1A and p53 were mutually altered in pure-type clear cell carcinoma at immunohistochemical analysis. Altered expression of p53 in these clear cell carcinomas was associated with significant worse prognosis than that of ARID1A ( | |
|
|
| |
The effect of antioxidative stress agent on endometriosis and the suggested mechanism.
| Drugs | Authors | Study type | Effects | Mechanism |
|---|---|---|---|---|
| Vitamins C and E | Santanam et al. [ | Human clinical study | Decreased pelvic pain, dysmenorrhea, dyspareunia, PF inflammatory markers, normal T-cell expression and secretion, interleukin-6, and monocyte chemotactic protein-1 | ↓ oxidatively modified lipoproteins |
| Durak et al. [ | Animal study | Reduced endometriotic cyst volume, weight, growth, and natural killer cell content | Antioxidant and immune stimulator, stimulation of leukocyte functions, enhanced NK function | |
| Mier-Cabrera et al. [ | Human clinical study | Decreased OS markers: MDA, lipid hydroperoxides | Neutralizing ROS and RNS | |
|
| ||||
| Resveratrol | Amaya et al. [ | Animal study | Reduced expression of ESR1 and proliferative activity (Ki67), agonist and antagonist of estrogen in low and high concentrations, respectively | ↓ ESR1 in endometrial epithelium, action through nongenomic action of alternative estrogen receptors such as GPR30 |
|
| ||||
| Epigallocatechin-3-gallate | Matsuzaki and Darcha [ | In vitro + in vivo | Inhibited cell proliferation, migration and invasion of endometrial tissue, decreased fibrotic markers, prevented progression of fibrosis | ↓ transforming growth factor-b1-dependent increase in the mRNA expression of fibrotic markers, inhibited activation of MAPK and Smad signaling pathways in endometrial and endometriotic stromal cells |
|
| ||||
|
| Pittaluga et al. [ | In vitro + animal study | ↓ endometrioma mass, reduced immunohistochemical staining of the inflammation-related COX-2 protein, and decreased MMP-9 expression and activity | Switching cell behavior from proliferation toward differentiation and decreased both tissue inflammation and cell invasiveness |
| Porpora et al. [ | Clinical study | ↓ endometrioma size, pain reduction, decrease in cell invasive behavior, and ↓ in the inflammatory COX-2 | ↑ proteins of cell-cell junction complex such as E-cadherin and | |